-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TH6Eqi2B83pTTNPRPFo4ntmVUaUQrz5+lwyEoQOxqbYgaSag0eZWahrvJFHmwNO/
 mRR7NGWGkRLlE3GbVE5+Dg==

<SEC-DOCUMENT>0001104659-09-057375.txt : 20091002
<SEC-HEADER>0001104659-09-057375.hdr.sgml : 20091002
<ACCEPTANCE-DATETIME>20091001174950
ACCESSION NUMBER:		0001104659-09-057375
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20090930
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20091002
DATE AS OF CHANGE:		20091001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		091099723

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a09-29410_18k.htm
<DESCRIPTION>8-K
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED
STATES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES
AND EXCHANGE COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES
EXCHANGE ACT OF 1934</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of report (Date of earliest event reported): <b>September&nbsp;30,
2009</b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CELLDEX
THERAPEUTICS, INC.</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of Registrant as Specified in its Charter)</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-15006</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13-3191702</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other Jurisdiction</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer</font></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of Incorporation)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification No.)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">119 Fourth Avenue</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Needham, Massachusetts</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">02494-2725</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: <b>(781) 433-0771</b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check
the appropriate box below if the Form&nbsp;8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Written communications pursuant to Rule&nbsp;425
under the Securities Act (17 CFR 230.425)</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Soliciting material pursuant to Rule&nbsp;14a-12
under the Exchange Act (17 CFR 240.14a-12)</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
the Exchange Act (17 CFR 240.14d-2(b))</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
the Exchange Act (17 CFR 240.13e-4(c))</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ba.htm',USER='105976',CD='Oct  2 03:04 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.01.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Entry into a Material Definitive Agreement.</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
connection with the consummation of the Merger (as defined below), on October&nbsp;1,
2009, Celldex Therapeutics,&nbsp;Inc. (&#147;Celldex&#148;), CuraGen Corporation (&#147;CuraGen&#148;),
&#160;and The Bank of New York Mellon
(formerly the Bank of New York) (the &#147;Trustee&#148;) entered into a Supplemental
Indenture (the &#147;Supplemental Indenture&#148;) to the&nbsp;Indenture dated February&nbsp;17,
2004 between CuraGen and the Trustee (the &#147;Original Indenture&#148;) governing
CuraGen&#146;s 4.0% Convertible Subordinated Notes due 2011 (the &#147;Notes&#148;).&#160; The Supplemental Indenture modifies the
Original&nbsp;Indenture by providing that (i)&nbsp;the Notes shall be
convertible into the kind and amount of shares of stock and other securities or
property or assets (including cash) which the holders thereof would have been
entitled to receive had such Notes been converted into CuraGen common stock
immediately prior to the Merger (as defined below) and (ii)&nbsp;adjustments to
the conversion rate of the Notes shall be made in the same manner as the
Original Indenture prior to the execution of the Supplemental Indenture.&#160; In&nbsp;addition, the
Supplemental&nbsp;Indenture also adds or substitutes Celldex in certain
provisions of, and modifies certain&nbsp;definitions and section references in,
the Original Indenture to give effect to the modifications
described&nbsp;above.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Supplemental Indenture became operative upon the effectiveness of the
Merger.&#160; The description of the
Supplemental Indenture contained in this Item 1.01 does not purport to be
complete and is qualified in its entirety by reference to the Supplemental
Indenture which is attached as Exhibit&nbsp;4.1 of this Current Report on Form&nbsp;8-K
and incorporated herein by reference.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2.01.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Completion of Acquisition or Disposition of Assets.</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On
October&nbsp;1, 2009, Cottrell Merger Sub,&nbsp;Inc. (the &#147;Merger Sub&#148;), a
subsidiary of Celldex, merged with and into CuraGen (the &#147;Merger&#148;) in
accordance with the Agreement and Plan of Merger, dated May&nbsp;28, 2009,
among CuraGen, Merger Sub and Celldex (the &#147;Merger Agreement&#148;).&nbsp;&nbsp;As a
result of the Merger, CuraGen became a wholly-owned subsidiary of Celldex.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant
to the terms of the Merger Agreement, each outstanding share of CuraGen common
stock was converted into the right to receive 0.2739 shares of Celldex common
stock.&nbsp;&nbsp;Celldex will issue approximately 16,629,981 shares of its
common stock in exchange for outstanding shares of CuraGen common stock in
connection with the Merger.&#160; In addition,
at the Effective Time (as defined in the Merger Agreement) all outstanding
options to acquire shares of CuraGen common stock (i)&nbsp;under CuraGen&#146;s 2007
Stock Incentive Plan were converted into options to acquire shares of Celldex
common stock, as adjusted pursuant to the Merger Agreement, and (ii)&nbsp;under
CuraGen&#146;s 1997 Employee, Director and Consultant Stock Plan were terminated.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
description of the Merger contained in this Item 2.01 does not purport to be
complete and is qualified in its entirety by reference to the Merger Agreement,
which is attached as Exhibit&nbsp;2.1 of this Current Report on Form&nbsp;8-K
and incorporated herein by reference.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 1.0in;text-autospace:none;text-indent:-1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.02.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant
to the terms of the Merger Agreement, in connection with the consummation of
the Merger, the board of directors of Celldex expanded the size of the board
from eight to nine members and appointed Timothy M. Shannon, the Chief
Executive Officer and a director of CuraGen prior to the Merger, to fill the
newly created board position, effective immediately after the Effective Time,
to serve until the election and qualification of his successor or his earlier
death, resignation or removal.&#160; Mr.&nbsp;Shannon
will not serve on any committees of the board of directors.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ba.htm',USER='105976',CD='Oct  2 03:04 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
his capacity as a director of Celldex, Mr.&nbsp;Shannon will receive
compensation as a non-employee director in accordance with Celldex&#146;s non-equity
director compensation practices described in Celldex&#146;s Annual Proxy Statement
filed with the Securities&nbsp;and Exchange Commission on August&nbsp;25, 2008.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Other Events.</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At a special meeting of the stockholders of Celldex
held on September&nbsp;30, 2009, Celldex&#146;s stockholders approved the issuance
of Celldex common stock in connection with the Merger.&#160; A copy of the press release regarding the stockholder
vote is attached as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K
and is incorporated herein by reference.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On
October&nbsp;1, 2009, CuraGen and Celldex issued a joint press release
announcing the effectiveness of the Merger and the consummation of the
transactions contemplated by the Merger Agreement.&#160; A copy of the press release is attached as Exhibit&nbsp;99.2
to this Current Report on Form&nbsp;8-K and is incorporated herein by
reference.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Financial Statements and Exhibits.</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;Financial statements of business acquired</font></u></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
financial statements required by Item 9.01(a)&nbsp;of Form&nbsp;8-K will be
filed by amendment to this Current Report on Form&nbsp;8-K not later than 71 days
from the date that the initial report on Form&nbsp;8-K must be filed.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;Pro Forma Financial Information</font></u></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
pro forma financial statements required by Item 9.01(b)&nbsp;of Form&nbsp;8-K
will be filed by amendment to this Current Report on Form&nbsp;8-K not later
than 71 days from the date that the initial report on Form&nbsp;8-K must be
filed.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Exhibits</font></u></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.26%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;Number</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.32%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="86%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:86.42%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.32%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement and Plan of Merger, dated May&nbsp;28,
  2009, by and among Celldex, CuraGen, and Merger Sub (incorporated by
  reference to Celldex&#146;s Current Report on Form&nbsp;8-K filed on May&nbsp;29,
  2009).</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.32%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.32%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Supplemental
  Indenture, dated September&nbsp;30, 2009, by and among Celldex, CuraGen,
  Merger Sub, and Trustee.</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.32%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.32%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release dated September&nbsp;30, 2009.</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.32%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.2</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.32%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release dated October&nbsp;1, 2009.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ba.htm',USER='105976',CD='Oct  2 03:04 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:17.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.58%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX THERAPEUTICS, INC.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.58%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.58%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.58%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.82%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  Avery W. Catlin</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.58%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="44%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:44.82%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:
  Avery W. Catlin</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.58%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.6%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.82%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:
  Senior Vice President / Chief Financial Officer</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:
October&nbsp;1, 2009</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ba.htm',USER='105976',CD='Oct  2 03:04 2009' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT INDEX</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.26%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;Number</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="86%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:86.5%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement and Plan of Merger, dated May&nbsp;28,
  2009, by and among Celldex, CuraGen, and Merger Sub (incorporated by
  reference to Celldex&#146;s Current Report on Form&nbsp;8-K filed on May&nbsp;29,
  2009).</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Supplemental
  Indenture, dated September&nbsp;30, 2009, by and among Celldex, CuraGen,
  Merger Sub, and Trustee.</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release dated September&nbsp;30, 2009.</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.2</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.24%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release dated October&nbsp;1, 2009.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ba.htm',USER='105976',CD='Oct  2 03:04 2009' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>a09-29410_1ex4d1.htm
<DESCRIPTION>EX-4.1
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:right;text-autospace:none;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 4.1</font></b></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="right" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:right;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Execution Copy</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THIS SUPPLEMENTAL INDENTURE, dated as of September&nbsp;30,
2009 (this &#147;<u>Supplemental Indenture</u>&#148;), is by and among CuraGen
Corporation (the &#147;<u>Company</u>&#148;), Celldex Therapeutics,&nbsp;Inc. (&#147;<u>Parent</u>&#148;)
and The Bank of New York Mellon (formerly, The Bank of New York), as trustee
under the indenture referred to below (the &#147;<u>Trustee</u>&#148;).</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">W I T N E
S S E T H</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Company and Trustee have heretofore
executed and delivered to the Trustee an indenture (as amended, supplemented or
otherwise modified, the &#147;<u>Indenture</u>&#148;), dated as of February&nbsp;17,
2004, providing for the issuance of the Company&#146;s 4.0% Convertible Subordinated
Notes due 2011 (the &#147;<u>Securities</u>&#148;);</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Company, Parent and Cottrell Merger Sub,&nbsp;Inc.
(&#147;<u>Merger Sub</u>&#148;), a wholly-owned subsidiary of Parent, entered into the
Agreement and Plan of Merger, dated as of May&nbsp;28, 2009 (the &#147;<u>Merger
Agreement</u>&#148;), pursuant to which (i)&nbsp;Merger Sub will merge with and into
the Company with the Company continuing as the surviving corporation (the &#147;<u>Merger</u>&#148;);
and (ii)&nbsp;each issued and outstanding share of common stock, par value
$0.01 per share, of the Company outstanding immediately prior to the time at
which the Merger becomes effective (&#147;<u>Effective Time</u>&#148;), shall be
converted into the right to receive, and shall become exchangeable in
accordance with the Merger Agreement for, 0.2739 shares of common stock, par
value $0.001 per share, of Parent (the &#147;<u>Parent Common Stock</u>&#148;);</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, pursuant to Section&nbsp;12.4 of the
Indenture, as a condition to the consummation of the transactions contemplated
by the Merger Agreement, the Company is required to execute a supplemental
indenture (i)&nbsp;providing that the Securities shall be convertible into the
kind and amount of shares of stock and other securities, property or assets,
which Holders would have been entitled to receive upon the Effective Time had
such Securities been converted into Common Stock immediately prior to the
Effective Time; and (ii)&nbsp;providing for adjustments of the Conversion Rate
which shall be as nearly equivalent as may be practicable to the adjustments
provided for in Article&nbsp;XII of the Indenture; and</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, pursuant to Section&nbsp;11.1 of the
Indenture, the Company may amend or supplement the Indenture in certain
circumstances without notice to or consent of any Holder.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, for and in consideration of the
foregoing premises, it is mutually covenanted and agreed, for the equal and ratable
benefit of the Holders of the Securities, as follows:</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Capitalized Terms</font></u><font size="2" style="font-size:10.0pt;">. Capitalized terms used herein without definition
shall have the meanings assigned to them in the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment to Section&nbsp;1.1 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">. Section&nbsp;1.1 of the Indenture is
hereby amended by inserting each of the following definitions in addition to
the definitions, or in place of the corresponding definition of such term, as
applicable, in the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Board of Directors&#148; means either the board of
directors of the Company or Parent, as the case may be, or any duly authorized
committee of such Board.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Common Stock&#148; means (a)&nbsp;prior to the Effective
Time, the common stock, par value $0.01 per share, of the Company; and (b)&nbsp;after
the Effective Time, the Parent Common Stock or any other shares of Equity
Interest of Parent into which such Common Stock shall be reclassified or
changed; provided, that after the consummation of any transaction referred to
in Section&nbsp;12.4, all references to &#147;Common Stock&#148; shall, to the extent
necessary to protect the interests of the Holders, become references to &#147;Applicable
Stock.&#148;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Conversion Rate&#148; means (a)&nbsp;prior to the
Effective Time, 103.2429 shares of Common Stock, which is the number of shares
of Common Stock issuable upon conversion of each $1,000 of Principal Amount of
Securities immediately prior to the Effective Time; and (b)&nbsp;after the
Effective Time, the number of shares of </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ke.htm',USER='105976',CD='Oct  2 03:05 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common Stock issuable
upon conversion of each $1,000 of Principal Amount of the Securities, which is
initially 28.27823 shares, subject to adjustments as set forth in this
Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Effective Time&#148; means the time at which the merger
becomes effective under Delaware law pursuant to the Agreement and Plan of
Merger among the Company, Parent and Cottrell Merger Sub,&nbsp;Inc. (the &#147;<u>Merger
Sub</u>&#148;), a wholly-owned subsidiary of Parent, dated as of May&nbsp;28, 2009.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Fundamental Change&#148; means the occurrence of any of
the following events: (i)&nbsp;any &#147;person&#148; or &#147;group&#148; (as such terms are used
in Sections 13(d)&nbsp;and 14(d)&nbsp;of the Exchange Act), becomes the &#147;beneficial
owner&#148; (as defined in Rules&nbsp;13d-3 and 13d-5 under the Exchange Act, except
that a Person shall be deemed to have beneficial ownership of all shares that
such Person has the right to acquire, whether such right is exercisable
immediately or only after the passage of time), directly or indirectly, of more
than 50% of the total outstanding Voting Stock of the Company or Parent; (ii)&nbsp;during
any period of two consecutive years, individuals who at the beginning of such
period constituted the Board of Directors of the Company or Parent (together
with any new directors whose election to such Board of Directors or whose
nomination for election by the stockholders of the Company or Parent, as the
case may be, was approved by a vote of at least 66</font><font size="1" style="font-size:6.0pt;position:relative;top:-3.0pt;">2</font><font size="2" style="font-size:10.0pt;">/</font><font size="1" style="font-size:6.0pt;">3</font><font size="2" style="font-size:10.0pt;">% of the directors then still in office who were either directors at
the beginning of such period or whose election or nomination for election was
previously so approved) cease for any reason to constitute a majority of such
Board of Directors then in office; (iii)&nbsp;the Company or Parent consolidates
with or merges with or into any Person or conveys, transfers, sells or
otherwise disposes of or leases all or substantially all of its assets to any
Person, or any corporation consolidates with or merges into or with the Company
or Parent, in any such event pursuant to a transaction in which the outstanding
Voting Stock of the Company or Parent is changed into or exchanged for cash,
securities or other property, other than (1)&nbsp;any such transaction where
the outstanding Voting Stock of the Company or Parent, as the case may be, is
not changed or exchanged at all (except to the extent necessary to reflect a
change in the jurisdiction of incorporation of the Company or Parent, as the
case may be) or (2)&nbsp;where the stockholders of the Company or Parent, as
the case may be, immediately before such transaction own, directly or
indirectly, immediately following such transaction, more than 50% of the total
outstanding Voting Stock of the surviving corporation; or (iv)&nbsp;the Company
or Parent is liquidated or dissolved or adopts a plan of liquidation or dissolution
other than in a transaction which complies with the provisions described under Article&nbsp;VII.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A &#147;Fundamental Change&#148; shall not be deemed to have
occurred if either:</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;the last Closing Sale Price of the Common
Stock for each of at least five Trading Days within:</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the period of the ten consecutive Trading Days
immediately after the later of the Fundamental Change or the public
announcement of the Fundamental Change, in the case of a Fundamental Change
resulting solely from a Fundamental Change in clause (i)&nbsp;of the definition
of Fundamental Change; or</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(y)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the period of the ten consecutive Trading Days
immediately preceding the Fundamental Change, in the case of a Fundamental
Change resulting from a Fundamental Change in clauses (ii), (iii)&nbsp;or (iv)&nbsp;of
the definition of Fundamental Change</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">is at least equal to 105%
of the quotient where the numerator is the Principal Amount and the denominator
is the Conversion Rate in effect on each of such five Trading Days, with such
calculation being made for each Trading Day; or</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp;in
the case of a merger or consolidation described in clause (iii)&nbsp;of the
definition of Fundamental Change, at least 95% of the consideration, excluding
cash payments for fractional shares and cash payments pursuant to dissenters&#146;
approval rights, in the merger or consolidation constituting the Fundamental
Change, consists of common stock traded on a U.S. national securities exchange
or quoted on the Nasdaq Global Market (or which shall be so traded or quoted
when issued or exchanged in connection with such Fundamental Change) and as a
result of such transaction or transactions the Securities become convertible
solely into such common stock.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ke.htm',USER='105976',CD='Oct  2 03:05 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Officer&#148; means the Chief Executive Officer, the
President, the Chief Financial Officer, any Vice President, the Treasurer or
the Secretary of the Company or Parent, as the case may be.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Officers&#146; Certificate,&#148; when used with respect to the
Company or Parent, as the case may be, means a written certificate containing
the information specified in Section&nbsp;14.4 and Section&nbsp;14.5, signed in
the name of the Company or Parent, as applicable, by any two Officers, at least
one of whom is the Chief Executive Officer or the Chief Financial Officer, and delivered
to the Trustee. An Officers&#146; Certificate given pursuant to Section&nbsp;6.3
shall be signed by two Officers, one of whom must be the principal executive
officer, the principal financial officer or the principal accounting officer of
the Company or Parent, as applicable.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Opinion of Counsel&#148; means a written opinion
containing the information specified in Section&nbsp;14.4 and Section&nbsp;14.5,
from legal counsel who is reasonably acceptable to the Trustee. The counsel may
be an employee of, or counsel to, the Company or Parent.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Parent&#148; means Celldex Therapeutics,&nbsp;Inc., a
Delaware corporation, until a successor replaces it pursuant to the applicable
provisions of this Indenture and, thereafter, means such successor.&#160; The foregoing sentence shall likewise apply to
any subsequent successor or successors to such successors.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;6.3 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">. The words &#147;and Parent&#148; are hereby
inserted after the word &#147;Company&#148; the first time it appears. The words &#147;or the
Parent, as applicable,&#148; are hereby inserted after the word &#147;Company&#148; the second
time it appears.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;6.4 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">.&#160;
The words &#147;and Parent&#148; are hereby inserted after the word &#147;Company&#148; where
it appears in Section&nbsp;6.4 of the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;7.1 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">.&#160; The
words &#147;The Company shall not&#148; appearing at the beginning of Section&nbsp;7.1
are hereby replaced with the words &#147;Neither the Company nor Parent shall.&#148; The
words &#147;or Parent, as applicable,&#148; are hereby inserted after the word &#147;Company&#148;
each other time it appears in Section&nbsp;7.1, except for the first appearance
of the word &#147;Company&#148; in the last sentence of Section&nbsp;7.1, after which the
word &#147;Parent&#148; is hereby inserted.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;8.1 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">.&#160;
The words &#147;or Parent&#148; are hereby inserted after the word &#147;Company&#148; in Section&nbsp;8.1(c)&nbsp;and
each time it appears in Section&nbsp;8.1(g), (h), (i), (j)&nbsp;and (k)&nbsp;of
the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;8.2 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">.&#160;
The words &#147;or Parent (as applicable)&#148; are hereby inserted after the word
&#147;Company&#148; where it appears in Section&nbsp;8.2 of the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Article&nbsp;11 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">. The word, &#147;Parent&#148; is hereby inserted
after the word &#147;Company&#148; in the preamble to Section&nbsp;11.1 of the Indenture
and each time it appears in Section&nbsp;11.1(i)&nbsp;. The words &#147;or Parent&#148;
are hereby inserted after the word &#147;Company&#148; in Sections 11.1(a), 11.1(b),
11.1(h), 11.1(k)&nbsp;and 11.2 of the Indenture. The words &#147;or Parent&#146;s&#148; are
hereby inserted after the word &#147;Company&#146;s&#148; in Sections 11.1(c)&nbsp;and 11.1(d)&nbsp;of
the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment to Section&nbsp;12.1 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">. Section&nbsp;12.1 of the Indenture is
amended and restated in its entirety to read as follows:</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt .75in;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Section&nbsp;12.1. <u>Conversion Right</u>.</font></p>

<p align="left" style="margin:0in 0in .0001pt .75in;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;Subject to and upon compliance with the
provisions of this Article&nbsp;XII, a Holder of a Security shall have the
right, at such Holder&#146;s option, to convert all or any portion (if the portion
to be converted is $1,000 or an integral multiple of $1,000) of the Principal
Amount of such Security into a number of shares of Common Stock equal to the
product of (x)&nbsp;the Conversion Rate in effect on the date of conversion
times (y)&nbsp;the quotient of the Principal Amount at Issuance of the Security
or portion thereof surrendered for conversion divided by 1,000:</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ke.htm',USER='105976',CD='Oct  2 03:05 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">At any time prior to Stated Maturity
unless such Security has been previously redeemed or repurchased by the
Company; or</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">as provided in clause (b)&nbsp;of this Section&nbsp;12.1.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to any
conversion of a Security during a Registration Default Period following
satisfaction of any of the conditions to conversion described in this Indenture
(and during the prescribed time periods in respect thereof), a Holder shall be
entitled to 103% of the number of shares of Common Stock that the Holder would
have otherwise been entitled to upon conversion.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;(i)&nbsp;In the event that:</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)&nbsp; Parent distributes to all holders of its
Common Stock rights or warrants entitling them (for a period expiring within 60
days of the Record Date for such distribution) to subscribe for or purchase
Common Stock at a price per share of Common Stock less than the Closing Sale
Price of the Common Stock on the Business Day immediately preceding the
announcement of such distribution;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)&nbsp;Parent distributes to all holders of its
Common Stock cash or other assets, debt securities or rights or warrants to
purchase its securities, including the declaration of any cash dividends,
payable quarterly or otherwise, where the Fair Market Value (as determined by
the Board of Directors) of such distribution per share of Common Stock exceeds
10% of the Closing Sale Price of the Common Stock on the Business Day
immediately preceding the date of declaration of such distribution; or</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)&nbsp;a Fundamental Change occurs,</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">then, in each case, the
Securities may be surrendered for conversion at any time on and after the date
that Parent or the Company gives notice to the Holders of such right, which
shall be, in the case of (A)&nbsp;or (B), not less than 15 Business Days prior
to the Ex-Dividend Time for such distribution, or, in the case of (C), within
15 Business Days after the occurrence of the Fundamental Change, until 5:00&nbsp;p.m.,
New York City time, on the earlier of the Business Day immediately preceding
the Ex-Dividend Time and the date Parent or the Company announces that such
distribution shall not take place in the case of (A)&nbsp;or (B), or within 20
Business Days of Parent&#146;s or the Company&#146;s delivery of the notice of the
Fundamental Change in the case of (C); provided, however, that in the case of (A)&nbsp;or
(B), a Holder of Securities may not surrender Securities for conversion if the
Holder shall otherwise participate in such distribution without conversion.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&nbsp;In addition, in the event that Parent or
Company consolidates with or merges into another corporation, or is a party to
a binding share exchange pursuant to which the Common Stock would be converted
into cash, securities or other property as set forth in Section&nbsp;12.4, then
the Securities may be surrendered for conversion at any time from and after the
date which is 15 calendar days prior to the date announced by Parent as the
anticipated effective time of such transaction until 15 calendar days after the
actual date of such transaction.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&nbsp;Notwithstanding the foregoing, a Security in
respect of which a Holder has delivered a Fundamental Change Purchase Notice,
as the case may be, exercising such Holder&#146;s right to require the Company to
repurchase such Security may be converted only if such Fundamental Change Purchase
Notice is withdrawn in accordance with Section&nbsp;4.2(b)&nbsp;or Section&nbsp;5.2(b)&nbsp;prior
to 5:00&nbsp;p.m., New York City time, on the Business Day immediately
preceding such Purchase Date or Fundamental Change Purchase Date.&#148;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment to Section&nbsp;12.2 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">. The second paragraph of Section&nbsp;12.2(b)&nbsp;of
the Indenture is hereby amended in its entirety to read as follows:</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Except as described in Section&nbsp;12.9, the Company
and Parent will not make any payment in cash or Common Stock or other
adjustment for accrued and unpaid interest or Additional Interest on any
Securities when they are converted. The Company&#146;s and Parent&#146;s delivery to the
Holder of the full number of shares of Common Stock into which the Security is
convertible, together with any cash payment for such Holder&#146;s fractional
shares, shall be deemed to satisfy the Company&#146;s obligation to pay the
Principal Amount of the Security and to satisfy its </font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ke.htm',USER='105976',CD='Oct  2 03:05 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">obligation to pay accrued
and unpaid interest and Additional Interest, if any through the conversion
date. As a result, accrued interest, and Additional Interest are deemed paid in
full rather than cancelled, extinguished or forfeited. Notwithstanding the
foregoing, accrued interest and Additional Interest, if any, will be payable
upon any conversion of Securities made concurrently with or after acceleration
of the Securities following an Event of Default.&#148;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;12.2 is
hereby amended by replacing the words &#147;the Company&#148; by the word &#147;Parent&#148; the eleventh
time it appears in Section&nbsp;12.2.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Sections 12.3, 12.7, and 12.10 of the
Indenture</font></u><font size="2" style="font-size:10.0pt;">. The
words &#147;the Company&#148; are hereby replaced by the word &#147;Parent,&#148; and the words &#147;the
Company&#146;s&#148; are hereby replaced by the word &#147;Parent&#146;s,&#148; each time the words &#147;the
Company&#148; appear in Sections 12.3 (except 12.3(e)), 12.7 and 12.10 of the
Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment to Section&nbsp;12.4 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">. Section&nbsp;12.4 is hereby amended by
adding the words &#147;or Parent&#148; after &#147;the Company&#148; in the title to Section&nbsp;12.4
and each time they appear in Section&nbsp;12.4.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;12.6 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">. The words &#147;or Parent&#148; are hereby
inserted after the word &#147;Company&#148; each time it appears in Section&nbsp;12.6 of
the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;12.9 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">.&#160;
The words &#147;or Parent&#148; are hereby inserted after the word &#147;Company&#148; the
third time it appears in Section&nbsp;12.9 of the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;12.11 and 12.12 of the
Indenture</font></u><font size="2" style="font-size:10.0pt;">. The
words &#147;or Parent&#148; are hereby inserted after the word &#147;Company&#148; each time it
appears in Sections 12.11 and 12.12 of the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;14.2 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">. Section&nbsp;14.2 of the Indenture is
hereby amended in its entirety to read as follows:</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Section&nbsp;14.2. <u>Notices</u>. Any request, demand,
authorization, notice, waiver, consent or communication shall be in writing and
delivered in person (including by commercial courier services) or mailed by
first-class mail, postage prepaid, addressed as follows or transmitted by
facsimile transmission (confirmed by guaranteed overnight courier) to the
following facsimile numbers:</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">if to
Parent or the Company:</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o Celldex
Therapeutics,&nbsp;Inc.</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">119
Fourth Avenue</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Needham,
MA 02494</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:
President&nbsp;&amp; Chief Executive Officer</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax
(781) 433-3191 and (908) 454-1911</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with a
copy (which shall not constitute notice) to:</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lowenstein
Sandler PC</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65
Livingston Avenue</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Roseland,
NJ 07068</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:
Anthony Pergola</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax
(973) 597-2445</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">if to
the Trustee:</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
Bank of New York</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101
Barclay Street, 8 West</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New
York, New York 10286</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:
Corporate Trust Administration</font></p>

<p style="margin:0in 0in .0001pt 48.95pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile
No.: (212)&nbsp;815-5707</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ke.htm',USER='105976',CD='Oct  2 03:05 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company, Parent or the Trustee by notice given to
the other in the manner provided above may designate additional or different
addresses for subsequent notices or communications.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any notice or communication given to a Holder shall be
mailed to the Holder, by first-class mail, postage prepaid, at the Holder&#146;s
address as it appears on the registration books of the Registrar and shall be
sufficiently given if so mailed within the time prescribed.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Failure to mail a notice or communication to a Holder
or any defect in it shall not affect its sufficiency with respect to other
Holders. If a notice or communication is mailed in the manner provided above,
it is duly given, whether or not received by the addressee.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the Company or Parent mails a notice or
communication to the Holders, it shall mail a copy to the Trustee and each
Registrar, Paying Agent, Conversion Agent, or co-registrar.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing, in the case of the
Trustee, notice must be actually received by the Corporate Trust Administration
office of the Trustee.&#148;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment to Section&nbsp;14.4 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">.&#160;
The words &#147;or Parent&#148; are hereby inserted after the word &#147;Company&#148; each
time it appears in Section&nbsp;14.4 of the Indenture.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment to Section&nbsp;14.9</font></u><font size="2" style="font-size:10.0pt;">. Section&nbsp;14.9 of the Indenture is
hereby amended in its entirety to read as follows:</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Section&nbsp;14.9. <u>Governing Law; Submission to
Jurisdiction; Service of Process</u>.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Indenture shall be governed by, and construed in
accordance with, the laws of the State of New York. The Company and Parent each
submits to the non-exclusive jurisdiction of the courts of the State of New
York and the courts of the United States of America, in each case located in
the Borough of Manhattan, New York, New York over any suit, action or
proceeding arising under or in connection with this Indenture or the
transactions contemplated hereby or the Securities. Each of the Company and
Parent waives any objection that it may have to the venue of any suit, action
or proceeding arising under or in connection with this Indenture or the
transactions contemplated hereby or the Securities in the courts of the State
of New York or the courts of the United States of America, in each case located
in the Borough of Manhattan, New York, New York, or that such suit, action or
proceeding brought in the courts of the State of New York or the courts of the
United States of America, in each case located in the Borough of Manhattan, New
York, New York, was brought in an inconvenient court and agrees not to plead or
claim the same.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each of the Company and Parent agrees that service of
all writs, process and summonses in any suit, action or proceeding arising
under or in connection with this Indenture or the transactions contemplated
thereby or the Securities against the Company in any court of the State of New
York or any United States Federal court, in each case, sitting in the Borough
of Manhattan, New York, New York, may be made upon Corporation Service Company
at 80 State Street, Albany, New York 12207, whom each of the Company and Parent
each irrevocably appoints as its authorized agent for service of process. Each
of the Company and Parent each represents and warrants that Corporation Service
Company has agreed to act as the Company&#146;s and Parent&#146;s agent for service of
process. The Company and Parent agree that such appointment shall be
irrevocable until the irrevocable appointment by the Company and Parent of a
successor in New York, New York as their authorized agent for such purpose and
the acceptance of such appointment by such successor. The Company and Parent
further agree to take any and all action, including the filing of any and all documents
and instruments that may be necessary to continue such appointment in full
force and effect as aforesaid. If Corporation Service Company shall cease to
act as the agent for service of process for the Company or Parent, the Company
or Parent, as applicable, shall appoint without delay, another such agent and
provide prompt written notice to the Trustee of such appointment.&#148;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments to Section&nbsp;14.10 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">.&#160; Section&nbsp;14.10
is hereby amended by adding the words &#147;or Parent&#148; after the words &#147;the Company&#148;
each time they appear.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ke.htm',USER='105976',CD='Oct  2 03:05 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendments of Section&nbsp;14.11 of the Indenture</font></u><font size="2" style="font-size:10.0pt;">. The first sentence of Section&nbsp;14.11
of the Indenture is hereby replaced with the following sentence: &#147;All agreements
of the Company and Parent in this Indenture and the Securities shall bind their
respective successors.&#148;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Ratification of Indenture; Supplemental Indenture Part&nbsp;of
Indenture</font></u><font size="2" style="font-size:10.0pt;">. Except
as expressly amended hereby, the Indenture is in all respects ratified and
confirmed and all the terms, conditions and provisions thereof shall remain in
full force and effect. This Supplemental Indenture shall form a part of the
Indenture for all purposes, and every Holder of Securities heretofore or
hereafter authenticated and delivered shall be bound hereby.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Governing Law</font></u><font size="2" style="font-size:10.0pt;">. This Supplemental Indenture shall be governed by,
and construed in accordance with, the laws of the State of New York.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Counterparts</font></u><font size="2" style="font-size:10.0pt;">. The parties may sign any number of copies of this Supplemental
Indenture. Each signed copy shall be an original, but all of them together
shall represent the same agreement.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Effect of Headings</font></u><font size="2" style="font-size:10.0pt;">. The section headings herein are for convenience only
and shall not affect the construction hereof.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">The Trustee</font></u><font size="2" style="font-size:10.0pt;">. The Trustee makes no representation or warranty as
to and shall not be responsible in any manner whatsoever for or in respect of
the validity or sufficiency of this Supplemental Indenture or for or in respect
of the recitals contained herein, all of which recitals are made solely by the
Company.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">The Trust Indenture Act</font></u><font size="2" style="font-size:10.0pt;">.&#160; This
Supplemental Indenture is subject to the provisions of the TIA that are
required to be a part of the Indenture and shall, to the extent applicable, be
governed by such provisions.&#160; If any
provision in this Supplemental Indenture limits, qualifies or conflicts with
another provision hereof which is required to be included herein by any
provision of the TIA, such required provision shall prevail.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Separability Clause</font></u><font size="2" style="font-size:10.0pt;">.&#160; In case any
provisions of this Supplemental Indenture, the Indenture or the Securities
shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or
impaired thereby.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Effectiveness</font></u><font size="2" style="font-size:10.0pt;">.&#160; This
Supplemental Indenture shall be deemed effective immediately prior to the
Effective Time.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ke.htm',USER='105976',CD='Oct  2 03:05 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the undersigned, being duly
authorized, have executed this Supplemental Indenture on behalf of the
respective parties hereto as of the date first above written.</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:left;text-autospace:none;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CELLDEX THERAPEUTICS,
  INC.</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Anthony S. Marucci</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony S. Marucci</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp;
  CEO</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CURAGEN CORPORATION</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Sean Cassidy</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sean Cassidy</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President&nbsp;&amp;
  Chief Financial Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THE BANK OF NEW YORK
  MELLON,</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">as Trustee
  </font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: </font></p>
  </td>
  <td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Carlos R. Luciano</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Carlos R. Luciano</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\105976\09-29410-1\task3736828\29410-1-ke.htm',USER='105976',CD='Oct  2 03:05 2009' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>a09-29410_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.1</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.84%;">
  <h1 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;"><b><font size="2" face="Times New Roman"><img width="204" height="63" src="g294101mmi001.jpg" alt="GRAPHIC"></font></b></h1>
  </td>
  <td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.18%;">
  <h1 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></h1>
  </td>
  <td width="51%" valign="bottom" style="padding:0in 0in 0in 0in;width:51.98%;">
  <h1 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;"><b><font size="2" face="Times New Roman"><img width="240" height="37" src="g294101mmi002.jpg"></font></b></h1>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:auto;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">FOR IMMEDIATE RELEASE/September&nbsp;30,
2009</font></b></h1>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.44%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony S. Marucci</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery W. Catlin</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.22%;">
  <p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Media:</font></u></p>
  </td>
 </tr>
 <tr>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.44%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and CEO</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.22%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Matthew Driscoll</font></p>
  </td>
 </tr>
 <tr>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.44%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex </font><font size="2" style="font-size:10.0pt;">Therapeutics</font><font size="2" style="font-size:10.0pt;">,&nbsp;Inc.</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex </font><font size="2" style="font-size:10.0pt;">Therapeutics</font><font size="2" style="font-size:10.0pt;">,&nbsp;Inc.</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.22%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BMC Communications Group</font></p>
  </td>
 </tr>
 <tr>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.44%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781) 433-0771</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781) 433-0771</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.22%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(973) 271-6085</font></p>
  </td>
 </tr>
 <tr>
  <td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.44%;">
  <p style="margin:0in -.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in -.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in -.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IR@celldextherapeutics.com</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.92%;">
  <p style="margin:0in -.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.22%;">
  <p style="margin:0in -.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">mdriscoll@bmccommunications.com</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Celldex and CuraGen Stockholders
Approve Acquisition of CuraGen Corporation</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEEDHAM, MA and Branford, CT (September&nbsp;30,
2009):&#160; </font></b><font size="2" style="font-size:10.0pt;">Celldex Therapeutics,&nbsp;Inc.
(Nasdaq: CLDX) and CuraGen Corporation (Nasdaq: CRGN) announced that, at
special meetings held earlier today, Celldex&#146;s stockholders approved the
issuance of shares of Celldex common stock pursuant to the previously disclosed
Agreement and Plan of Merger, dated as of May&nbsp;28, 2009, by and among
Celldex, Cottrell Merger Sub,&nbsp;Inc. and CuraGen, and that CuraGen&#146;s
stockholders approved the Agreement and Plan of Merger.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Following the closing of the
merger contemplated by the Agreement and Plan of Merger, each outstanding share
of CuraGen common stock will convert into the right to receive 0.2739 shares of
Celldex common stock and CuraGen will become a wholly-owned subsidiary of
Celldex.&#160; Celldex will issue
approximately 16,629,981 shares of its common stock in exchange for all outstanding
shares of CuraGen common stock in connection with the merger.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex currently
anticipates that the merger will close on October&nbsp;1, 2009.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Celldex Therapeutics,&nbsp;Inc.</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics is an
integrated biopharmaceutical company that applies its comprehensive Precision
Targeted Immunotherapy Platform to generate a pipeline of candidates to treat
cancer and other difficult-to-treat diseases. Celldex&#146;s immunotherapy platform
includes a complementary portfolio of monoclonal antibodies, antibody-targeted
vaccines and</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#150;
more &#150;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">119
FOURTH AVENUE&#160;&#160; NEEDHAM, MA&#160; 02494-2725 USA&#160;&#160; 781-433-0771&#160;&#160; FAX&#160;
781-433-0262</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">www.celldextherapeutics.com</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105541\09-29410-1\task3736338\29410-1-mm.htm',USER='105541',CD='Oct  1 22:41 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">immunomodulators
to create novel disease-specific drug candidates. For more information, please
visit http://www.celldextherapeutics.com.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About CuraGen Corporation</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CuraGen
Corporation is a biopharmaceutical company dedicated to improving the lives of
patients by developing promising pharmaceutical products that address unmet medical
needs. CuraGen&#146;s therapeutics are based on research into novel drug targets and
mechanisms that are believed to play a role in the underlying disease. CuraGen
has translated this research and understanding into a pipeline of protein,
antibody, and antibody-drug conjugate drugs. For more information, please visit
www.curagen.com</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Safe Harbor Statement Under the Private Securities
Litigation Reform Act of 1995:&#160; </font></i></b><em><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains </font></i></em><font size="2" style="font-size:10.0pt;">&#147;<em><i><font face="Times New Roman">forward-looking statements&#148; made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995, including those related to Celldex&#146;s strategic focus and the future
development and commercialization of Celldex&#146;s programs. Forward-looking
statements reflect management&#146;s current knowledge, assumptions, judgment and
expectations regarding future performance or events. Although Celldex management
believes that the expectations reflected in such statements are reasonable,
they give no assurance that such expectations will prove to be correct and you
should be aware that actual results could differ materially from those
contained in the forward-looking statements. Forward-looking statements are
subject to a number of risks and uncertainties, including, but not limited to,
the successful integration of the businesses, multiple technologies and
programs of CuraGen and Celldex; Celldex&#146;s ability to adapt APC Targeting
Technology</font></i></em></font><em><i><font size="1" face="Times New Roman" style="font-size:6.5pt;position:relative;top:-3.0pt;">TM</font></i></em><em><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;to develop new, safe and
effective vaccines against oncology and infectious disease indications; Celldex&#146;s
ability to successfully complete product research and further development of Celldex&#146;s
programs; the uncertainties inherent in clinical testing; Celldex&#146;s ability to
manage research and development efforts for multiple products at varying stages
of development; Pfizer&#146;s and Celldex&#146;s strategy and business plans concerning
the continued development and commercialization of CDX-110; the timing, cost
and uncertainty of obtaining regulatory approvals; the failure of the market
for the combined Companies&#146; programs to continue to develop; the inability to
obtain additional capital; the inability to protect the combined Companies&#146;
intellectual property; the loss of any executive officers or key personnel or
consultants; competition; changes in the regulatory landscape or the imposition
of regulations that affect the combined Companies&#146; products; and other risks
detailed from time to time in Celldex&#146;s filings with the Securities and
Exchange Commission, including Celldex&#146;s Form&nbsp;10-K for the fiscal year
ended&nbsp;December&nbsp;31, 2008, and&nbsp;its&nbsp;Forms 10-Q and 8-K</font></i></em><i><font size="2" style="font-size:10.0pt;font-style:italic;">.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CRGN-P</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">###</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105541\09-29410-1\task3736338\29410-1-mm.htm',USER='105541',CD='Oct  1 22:41 2009' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>a09-29410_1ex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.2</font></b></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 align="center" style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;"><b><font size="2" face="Times New Roman"><img width="204" height="76" src="g294101mni001.jpg" alt="GRAPHIC"></font></b></h1>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">FOR IMMEDIATE
RELEASE/October&nbsp;1, 2009</font></b></h1>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony
  S. Marucci</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery
  W. Catlin</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">For
  Media:</font></u></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President
  and CEO</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief
  Financial Officer</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Matthew
  Driscoll</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex </font><font size="2" style="font-size:10.0pt;">Therapeutics</font><font size="2" style="font-size:10.0pt;">,&nbsp;Inc.</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex </font><font size="2" style="font-size:10.0pt;">Therapeutics</font><font size="2" style="font-size:10.0pt;">,&nbsp;Inc.</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BMC
  Communications Group</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781)
  433-0771</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781)
  433-0771</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(212)
  477-9007 x20</font></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in -.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in -.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IR@celldextherapeutics.com</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.34%;">
  <p style="margin:0in -.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">mdriscoll@bmccommunications.com</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Celldex Therapeutics Announces Completed Acquisition of CuraGen
Corporation</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEEDHAM, Mass (October&nbsp;1, 2009):&#160;
</font></b><font size="2" style="font-size:10.0pt;">Celldex Therapeutics,&nbsp;Inc. (Nasdaq: CLDX) announced today the
successful completion of its acquisition of CuraGen Corporation (Nasdaq: CRGN)
pursuant to the previously disclosed Agreement and Plan of Merger, dated as of May&nbsp;28,
2009, by and among CuraGen, Celldex and Celldex&#146;s merger subsidiary, Cottrell
Merger Sub,&nbsp;Inc. The Agreement and Plan of Merger was approved by CuraGen&#146;s
stockholders and the issuance of shares of Celldex common stock was approved by
Celldex&#146;s stockholders at special stockholder meetings held on September&nbsp;30,
2009. Concurrent with the closing of the merger, Celldex added one position to
its Board of Directors and Dr.&nbsp;Timothy Shannon, President and Chief
Executive Officer of CuraGen, joined the Celldex Board of Directors.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Celldex is focused on advancing our pipeline of targeted immunotherapeutics
and we look forward to integrating CuraGen&#146;s assets to augment our Precision
Targeted Immunotherapy Platform,&#148; stated Anthony Marucci, President and Chief
Executive Officer of Celldex. &#147;We&#146;ve also significantly strengthened our
balance sheet and look forward to a very productive and promising 2010.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The purchase price for CuraGen was approximately $93.5 million after
giving effect to the adjustments described in the Agreement and Plan of Merger
to reflect CuraGen&#146;s net cash balance of approximately $53.5 million.&#160; As a result of the merger, CuraGen has become
a wholly owned subsidiary of Celldex.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#150;
more &#150;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">119
FOURTH AVENUE&#160;&#160; NEEDHAM, MA&#160; 02494-2725 USA&#160;&#160; 781-433-0771&#160;&#160; FAX&#160;
781-433-0262</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">www.celldextherapeutics.com</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105976\09-29410-1\task3736333\29410-1-mn.htm',USER='105976',CD='Oct  1 22:37 2009' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Celldex Therapeutics,&nbsp;Inc.</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics is an
integrated biopharmaceutical company that applies its comprehensive Precision
Targeted Immunotherapy Platform to generate a pipeline of candidates to treat
cancer and other difficult-to-treat diseases. Celldex&#146;s immunotherapy platform
includes a complementary portfolio of monoclonal antibodies, antibody-targeted
vaccines and immunomodulators to create novel disease-specific drug candidates.
For more information, please visit http://www.celldextherapeutics.com.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995:&#160; </font></i></b><em><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains </font></i></em><font size="2" style="font-size:10.0pt;">&#147;<em><i><font face="Times New Roman">forward-looking statements&#148; made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995, including those related to the Company&#146;s strategic focus and the
future development and commercialization of our programs. Forward-looking
statements reflect management&#146;s current knowledge, assumptions, judgment and
expectations regarding future performance or events. Although management
believes that the expectations reflected in such statements are reasonable,
they give no assurance that such expectations will prove to be correct and you
should be aware that actual results could differ materially from those
contained in the forward-looking statements. Forward-looking statements are
subject to a number of risks and uncertainties, including, but not limited to,
the successful integration of the businesses, multiple technologies and
programs of CuraGen and Celldex; our ability to adapt APC Targeting Technology</font></i></em></font><em><i><font size="1" face="Times New Roman" style="font-size:6.5pt;position:relative;top:-3.0pt;">TM</font></i></em><em><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;to develop new, safe and
effective vaccines against oncology and infectious disease indications; our
ability to successfully complete product research and further development of
our programs; the uncertainties inherent in clinical testing; our ability to
manage research and development efforts for multiple products at varying stages
of development; Pfizer&#146;s and our strategy and business plans concerning the
continued development and commercialization of CDX-110; the timing, cost and
uncertainty of obtaining regulatory approvals; the failure of the market for
the Company&#146;s programs to continue to develop; the inability to obtain
additional capital; the inability to protect the Company&#146;s intellectual
property; the loss of any executive officers or key personnel or consultants;
competition; changes in the regulatory landscape or the imposition of
regulations that affect the Company&#146;s products; and other risks detailed from
time to time in the Company&#146;s filings with the Securities and Exchange
Commission, including the Company&#146;s Form&nbsp;10-K for the fiscal year
ended&nbsp;December&nbsp;31, 2008, and&nbsp;its&nbsp;Forms 10-Q and 8-K</font></i></em><i><font size="2" style="font-size:10.0pt;font-style:italic;">.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CRGN-P</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">###</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105976\09-29410-1\task3736333\29410-1-mn.htm',USER='105976',CD='Oct  1 22:37 2009' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g294101mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g294101mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``_`,P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBLO7/$
M.F>';+[5J5RL2'A%ZLY]%'>FDV[(3:6K-2BO']1^-<WFD:7I$8C'1[ESD_@O
M3\ZKVOQKU)90;O2+1X^XA=E/ZYKI6#K6O8R^L4^Y[117,^&/'6C>*1Y=K*T-
MV!EK:;AOP[,/I735SRC*+M)&JDI*Z"D)"C)(`]ZQ/%7B:V\+Z++?SC>P^6*(
M'EW/05Y[:>'/$7C9!J7B'4KFWMY?FBLX#M`4]..@_')JX4KKFD[(F4[.R5V>
MMB:)C@2(3Z!A3Z\JD^%.FQ+N@N;^"4=)$D&14.E^(-<\#ZY;:9KEVU_H]TVR
M*Z?):,_4\\=P:KV49?!*[[;$\[7Q(];HH!R,CI4<MQ#`,S31QCU=@/YU@:DE
M&<4U)$E7=&ZNOJIR*Y3XBW#P^#-2$;,K&(8*G!'S"JC'FDHB;LKG69&,Y&*6
MO)-8NYE^"%@1+()&@B)<,=WWO6O1O#+%_"ND,Q)8V<)))Y/R"KG2Y8WOU:)C
M.[MY&K13)9HH%W2RI&OJ[`"H9[E1;^;$ZNO8J<BLBRR"#T-%>;_!Z:6;2=6,
MLKR$7AP78G''O7H[,%4LQ``ZDFKJ0Y)N),)<T;BT5%%=6\S%8IXI&'4*X)J6
MH*"BBB@`HHHH`J:C?Q:=927$IPJ#)KSSQQX.7QA9IKVB7#374<>UH&;AP.P'
M\+>W>MKQS<L+6*$'AY.?P%<OH^LW6C77FP'*-_K(B>''^/O2CB)4JET<5>NE
M/DDM#R62-XI&CD1DD0E65A@J1V(IM>W>*_"6G>-M+?6])*P:E&IW@C`DP,E6
M]_0US_PY\#6=Y8IXEUID:S7+0P'H=IP6?VXX%>U'&4W3]H9^R=[+8B^'O@">
M[FAU_57DM+*$B2%=Q1Y,=R>H7^=>P:;J]IJL<SVCEEB?8<C&??Z5P/B'Q-)J
MS&WMLQ6*\!>A?W/M[59\"SE-6G@S\LL)./<'_P"O7C5L4ZU378JG7C&:A#;N
M9'CU_P"UO'_AW1Y3_H[2!V7L<M_]CC\:]82-8U"JH`'2O(_B(LND^)-&\0*A
M,=M,%DP.@SG]1NKUFTNH+ZTANK:19(9D#HZG@@UT5?X<&MM3JA\<B4J",$5S
MFO\`A.Q\0Q+;7R.80X<;&VD'ZUTE</\`$'Q?=>'[:UM-*9#J=U*%C5EW?+W.
M/<X%9THRE-*.Y<VE%N6Q+XZ\42^%M#@@T\;[^X(@M]WS$<?>]ST_&N>L?AF]
M_&+SQ%>WE[>RC<X\TA5/I[UG?$E+EM4\.O=7!A.X)).@^X^1E@*W/^$/\0#I
MXRU7'L!_C71&T*::E9NYB_>F[J]C*U3PC?\`A2-]5\,ZA>0RP#?);2/O611U
M^OT-:.OZ^GB7X63ZFJA'DAVRH/X7#`$?3O\`C4=WX/UA;>22Y\8ZCY*J2[2`
M8"]\\U1N-*L])^%>I1:?J0O[:1C()@N!G*@@?E5*2ERW=W=:V%9J]E96(]:_
MY(CIO_7O%_Z$:Z/4_%1\+_#72IX%#7DMI#%`I&0&*#G'?%<YK7_)$=-_Z]XO
M_0C57QB=GAOP;<2C-O"(?,],;$/]#345)I/^9B;:5UV1J:7\/+G6H%U+Q->W
MEU=SC>8A*0$!YP?\!3[[PI=>%(VU'P[>72F+YYK*9]\<RCJ!Z'%>IQ-')$DD
M9!1P&4CH0>E4-9\F*QDFF($<:EF)]`.:Y_K%1O7;MT-?912_4\\^$M]%9>%]
M:O9SLB2X,C>PVYJE866L?$VXEU+4;NXMM'60K;VL+;=V/\\GUJAX45[CX<>)
MD@!S)(Y4#N-O3\JL^#-`U/4_#-O<V'B>_M(MS*8(0-L;`\]_Q_&NJ=HRG.]G
M>WX&,;M1C:Z-B[^%VFQ1;K2:^M)UY699B<'U(JSX(\1:J-2O?"VN2^?>VREX
M)SUE3N">_!!!IC>#M?9<-XQU0CW4?XU'X9\-6]GXX2XG\2/>ZI;QD/;NOS[2
M.Y[#D5DY*46I2O\`)EV:DFE8T7N+KPUJANHS)+82G$D3,3L^G]*L>,?'MMHF
ME1'3F6YO[Q?]&C'.,\;B/8]O6G^.]9L/#^E/-<!9)I04BM^\A_P'<URNC+%:
MW6F:IJNF[8V&Y"XRT!/^<URPC[.TYKW?Z_`B3=)N,7H_P.E\`>&KS38)-5UB
MXFGU2[^9A)(2(@><8Z9]?RKMZ9"\<D2O$P9&&58="*?1.;F^9G3&*BK(X?QM
M"S1)(`<(^3^/%<57JVMV`N[9P5R",&O,[FPFMKL6[#[S!4;L<URU8ZW//QE-
M\W.C>T.]-IX>N`#C>SC_`,=K/\&7I_X5W%:9X\F7C\35.\N8K+3OLJW,<LH>
M0N(R<#C'<5E^#[Z*+2(8)I5C1HY%W-T!.<5Z5.B_JS36O_#FD+J*B^S+`Z5U
M7@.V9]6FN,?+'%MS[D__`%JYXV,IN8K>$K.\JAD,?((->F^'=)72=-6(X,K?
M-(WJ:\RG!\VO0PPM)NI=]"/7M%M]5LY;>XB$L,@PRG^8]Z\]M-)\8^#G>+0+
MJ*^T\MD6MP0"OTSC'X'\*]=QFH7MHGZJ*[85905MUV/2E!2UZGFK>*?B)=`P
MPZ#9V[GCS&;('OR:N^%_`]T-8_M_Q%=_;M3ZH/X(_I[_`,J[Q;2)3D**F``&
M`*IUG:T4EZ"5-7NW<Y;Q;X:@U_3I+2?(!^9)%'*,.A%<K87_`(_\.P+8BRM-
M8MXQMBE:3:P4=`><_G^=>IE0PP14)M(B<[12A5<5RM77F.4$W?9GF=W:^-?&
MBBRU&.VTC37(\Y(6W.X]*WO$7AO'@M]"TF%5`A$<2DX'4')/KU-=<PCMT+!>
M@Z#O6`-=GN-'U"Y:#RI8&<1L0,<=!U/([TI5W=6TMJ0U&._4YO5/#&IS_#.R
MT)(XS?1Q1HR[_ER#D\UKWOA9;_P?::5?+\R6L<;E.2CJH&1]#6S8:U!=L(IX
M)8)%A$VZ10`R]R,4ZTU^UO)XX?)EC68$P/(`!)CKCGC\:7MV_ON"=/\`0X#3
M9O'?A2`6%O;VNL64?$)=]K(/3KG\.:ENK?QAXOVP:S'!IFE[@98(&W/*!V)]
M*[:UU2SOGF,=M.(X=VZ4K\N1V'J:=8:Q:W=R+;[+-`[(9$\P#YE_`\?C5_6;
MZV5^XDH:*^AR_@+PM?:)H=_;W\<:M-<;XU5MP*XQS60N@>(_".J7%UX7DBFL
MYVW26$YP`?;/\\UWD?B6T+`_9KA;?S?*:<J-JMG'KG\:=?ZQ96US)$T$LOD@
M&=XP,1@^OK^%+ZR^9R?7</W?*M=CCI/$7Q!OD,$&@6-F[<><TN[;[XS6MX6\
M,OX8M+W4KES?ZQ=`O+)G&X]0H)Z#/>NB6\LENC"BEB(/M`8="M4;W7\1:=);
M6S21W3@$$<A3V'/6E*OI9))>0_=CJW<Y+1O"6JZ_XHDU[Q4J?NV_T:U5@RJ.
MWX#]37::KI,<]NR,FY&'(_K3TU*.'5+J)Y2L,-N)2I087U.>_P!*=9ZW#?2"
M-K:XA5T\R-Y%X=?PZ?0U-2KSO4<>1>[W,SPQ#J>G3/9RJ);#),;[AE/P]*ZF
ML;3=;MKZY$<%M.J,6"RE05..N<=/QK9K.-K:#I**C:+T$90P(-8FI:,DV'"`
MD$,`?45N4=:HT:N>2W'@*_FFE<WRCS&)_P!4>_XU!9_#>^@@2`:@N!W\D_XU
M[!L7T%&U?05O]9J[7(]G'<P]"T%--LX%E*R3I&$,H7&0.E;H&***Q;N[E));
M!1112&%%%%`!1110!#<IOB(%<^NB3?8;VU,ZE+AF9/DY0MUSSS734F!Z4FKD
MRBI;G/-I$GGB4OE1;?9RN.OO573=!FM9HW9XBD0(7;$`S?4UU>!Z4;0.U'*A
M>SC>Y@0Z3):Z1/:B8EI6<[U&"N[_``K.T_1;FRNHK@R0XC0HP2+!8'N3GK78
M8![4AC4C&*7*A>RCIY'%V.CW]S:M!++Y5LUP9&C*?,0&R,'T-6;K09[C4)ID
M>(>=C?YD6\KCNM=6J*HX%+M'I1R(2HQM8YFYTN[-VLEK.L7[C[.VY-WR^H]Z
M5]#E%G8P1S@26K*P<ID-CVS72[1Z48'I3Y45[.)SLVCO+=W4[OE)X1"5`Y'O
MFBRT^_A5?.O-\44?EHB)MS[GU-=%@>E&T>E%D')&]SE]*T*>'5(KJ29/W18Y
72/:TF>S=C74T@`'04M"26PXP459'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g294101mmi002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g294101mmi002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``E`/`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#UO6=8G-T-
M.L,B8L%9QUSZ#_&HAX6N'3S)+\_:.O0D9^N<U5\/?Z3K\D[\MAWY]2?_`*]=
MC0!SNBWE_#?/IUXDDFWI)C.WZGT-=%110!GZVS)HURRL58*,$'!ZBJ_AIWDT
M@,[LS>8W+')J?7?^0)=?[H_F*K^%_P#D##_KHU`$^ONR:+.R,58;<%3@]13/
M#KM)HT3.S,VYN6.3UIWB'_D!W'_`?YBF>&_^0)%_O-_.@#6KEO$\DHU&U2.5
MT#)CY6([UU-<IXH8+JEHQZ!`3_WU0!/_`,(U>?\`05D_\>_QJ"&]U#1M4CM+
MR8S0N1R3G@\9!ZUK'Q'I8!/GL?8(:Q'=_$6MQM%$RV\6`2>R@YY]S0!V%%%%
M`&'XFOGM;..*&1DEE;.5."`/\BJWAV]N/ML]G=R2,^,C>V2".HJ&Z_XFOBM(
M1\T4)`/IA>3^O%+K0.F^(+>^7A7P6Q[<']*`.JHI`0RA@<@C(-+0!DZ]JK:;
M;JD.//ESM)_A'K69#X=N[Z(3WMZZR.,A2-Q'UIFJC[1XKMX6Y4%!CVZUTEU?
MVMEM-S,(]^=N0>:`.>A_M;1;^*W.^[@D/`&3D=\9Z$5U-9W]O:7T^V)^1_PK
M1ZT`%<7!;W.I:S=6ZWDL05G8'<2/O=.M=IWKB;748],UR[FD1G4LZX7_`'J`
M-+_A&KS_`*"LG_CW^-7]+TF?3YWDEO6G#+M"G/'/7DU3_P"$NM/^?:;]*V;&
M[2^LTN45E5\X#=>N*`+%<MXG><:A;1PR2*63`"L1DYKJ:Y;Q(=NLV)'8#_T*
M@#4T"_-[IX60DS0G8^>I]#5/Q7+)'%:^7(Z99L[6(STIDW_$E\1K,.+6[X;T
M![_KS^-'B[_4VG^\W\A0!2T4BP\226\AQDM&,_F/Y5V-8NLZ']N87-LPCN1U
MYP&_'L:I"[\2QKY1MMS#C?L!_7.*`.B-S`MP+=I4$Q&0A/)%2USVF:%/]K^W
M:D^^;.Y4SGGU/^%=#0!G:[_R!+K_`'1_,56\+G_B3CVD;^E:T\*7$$D,@RCJ
M5-<S'9:UHLCK9J)X&.>F?T[&@#6\0G&AW'_`?YBF^&_^0)%_O-_.LN6VUW62
ML5RBP0@Y.1@?EU-=):6R6=K';Q_=08R>_O0!-7*>*`&U2S!&05`(_P"!5U=<
M_KNFW=YJ-K+;Q;T0`,<@8YS0!:O/#]E-:2);VZ138^1AZU4\-7WR/ITRA)HB
M2HQ@D=P?<5T-<]K&E7/]I0WVGK^]+#<!Q@^I]O6@#H:@O+@6EG-<'^!21]>U
M3(6**7`#8Y`.0#61XCBNKC3UBMH6D!?+[>N![4`9&C31Z=IFIZY=?<@C9R?4
M`;F_I532]8;QA\/+36'"_:D)\X+V920WZ8-8OQ5U'^P/AQ;Z4C[;C4'",!UV
MCYG_`%VC\:PO@5JZ.VJ^'IV^69/M$0)_X"X_(K^59.?OV.^&%OA'6ZW_``_K
M\CU[0+K[5I,63EX_W;?AT_3%:=<[X=L[RQN;F.6%E@/`<\9(/;\*Z*M3@.3U
MK-IXEM[ION'8V?H<&NCNK&UOPGVB(2A>5Y/?Z5#JVEIJEKY9.V1.4?T/H?:L
M6)O$6G(+=8!,B\*<;L#ZYH`@\16%M8S6HMHA&'SNP3SR*Z]?NCZ5RYTG5]6G
M234'6)%Z#`R![`?UKJ0,#%`!WKE-$56\27H901\_49_BKJZY-;#6;34[BYM;
M<?.S8+%3D$Y]:`.I\J/_`)YI_P!\BG`!1@``>@KG?.\3_P#/"+\E_P`:O:7)
MJ[SN-1C18]ORE0.N?8T`:M<KXF_Y"]E]!_Z%755@:YIUW>:C:RP1;T0#<<@8
M^;-`%_6K'^T-.DC`S(OSI]1V_&N8O[TWNBV>\_O87,;Y^G!_2NWKDM6T"[;4
M))+.'?#(=^`P&#W_`,^]`'6T444`%%%%`!1110`4444`%%%%`!1110`4444`
M8VM^$]"\1RPR:OIZ7;PJ5C+LPV@]>A%5]*\#>&M$OTOM,TJ.VND!"R([D@$8
M/4XHHI<JO>QHJM11Y5)V]3H:***9F%%%%`!1110`4444`%%%%`!1110`4444
#`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g294101mni001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g294101mni001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!,`,P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HH)P,UY[X_^(<OAJ5=.T^V+7LB;_.E4^6JGT_O'^573IRJ2Y8DRDHJ[/0J
M*^6M1\1:SJTIDOM3N9B>QD(4?0#@56M=4U"RE$MK?W4,@_B25@?YUVK+W;XC
MG^M+L?5U%>.^"?BEJ$FH6^EZU&]X)F$<4\29D!_V@/O#WKV*N2K1E2=I&\)J
M:N@KD]<^(WAW0KAK:6Y:XN5.&BMEWE3Z$]`?QK-^)?B6ZTS3H-,TUBM_J#^4
MC+U5>AQ[G(%6?"W@&QT*R0O$DMZPS+.XRQ)Z@9Z"JC",8\\^NR$Y2<N6)07X
MPZ(&'G:=JD*'J[PK@?DU=?HGB/2?$5L9M,O$G"_>7HR?4'D43:/&\94JC`CD
M,H(->8>)-'F\'ZW9^(=!A>,B4)<VT*DJRGV'8\C'KBG%4ZCY4K,3<X:O5'LE
M%0FZB6S%U*XBBV>8S.<!1C//I7#WGQ9T2.Y>#3[6]U%E."T$?RGZ$_X5E"G.
M?PHN4XQW9WU4=8U:VT32Y]0N]_DP+N?8,G&<<#\:YG2?B?H&HWBVEQ]HT^X8
MX47:;5)^O^-+\26/_"':B`>#$/\`T(52I24U&:W$YIQ;B:EQXOTRV\*Q>(I/
M.^PR*K*`GSX8X'%;%E=QW]A;WD.?*GC65-PP<,,C/YUY)K3'_A2&G#/'V>+_
M`-"->E>&I$C\(:2\C!46QB)9C@`;!S55*:C&Z[M"C-MV?8V*0L%ZFN%O_BMH
M5O=-;6,-WJ,BG!-M'E?P-26'Q$T?6Y198N+&]8X6&Z39O/H#T)J70J)7:&JD
M&[7-[P[XGT_Q/;W$VG^;L@E\I_,3;S[5LUYI\&O^01J^?^?T_P`JZ/Q%X_T/
MPW/]FN)GGO/^?>W7>P^OI55*3]HX05Q0G[BE(ZBBO/8_BYI:.OVW2]3M8F/$
MCQ9'UKM=/U:QU:P6^L+E+BW;HR'OZ$=C[&HG2G#62*C.,MF7:*S-/UZQU*ZD
MM8F=)X_O1R+M/OBM%W6-&=V"JHR6)P`*R3OL.,E)70ZBN?T/QCI7B*_N+73/
MM$WV?.^;RL1_@WO7054HN+LP33U1B>)M5;3=+D>,XE;Y4^IK`W:3X]TG^RM7
MC6.]49BD7@@_WD/\Q1XY<E8%SQO/\JXU':-U=&*LIR&!P0:Q=64)W1P5Z\H5
M;=#CO$WA?4/"NI&UO4W1MDPSJ/DD']#ZBLW3]/N]5OXK*Q@::YE.%1?YGT'O
M7O<$EOXK\(7-OK4*2[`RANAR%R&'H:R/AO!8Z3X#.KPP(VH3([R.W5MI.%]A
M7L0QUZ/.UJ-4XR::>CU+&@>'-+^'>F"\O2ESK$JXR.W^RGH/4UN^%O$$VL?:
MX[G:)4.]0HP`I[?A7G]Y>W&H737-S(7D;OV`]![5O>!RPU]E'W6@;/YBO'E7
ME4J79%/$-U5&.B,KQ:V_XJ^'!-CR=R]>F=Q_^M7KM>8_$G0KJZA@U*P5C>6#
M^:H4<E>O'N"`:Z7PEXXTSQ-I\9\^.&_50)K=V`8-W(SU%=TTYTHR731G9%\L
MVGU.IJI<BV@_TB>6.%0<;W8*/S-3R3PPH7DE1%'5F8`5Y+XPU<^/-<M/#&BO
MYUJDHDNKA/N#'OZ#G\<5G2I\[\NI<Y\J\RU\6-9+6^G:2ER(K:[DWSR@Y'EC
M'IU'.:O:5XC\!Z/81VEIJUO$BC!*HV6/J3CDUD_$G36LUTK4X8!+#ISJLD9&
M1Y?&,CTX_6NNTC3_``]KMA'>:?;V$L3C.!$F4/H1C@BMGR^QC>]M=C-<WM&<
MGXKUGP9KVES0'5+>28(3#+L.Y&[<XZ=JIP:O-JWP:NOM#EY;4&W+$Y)`*[?T
M./PKJ_$Z>'O#6ERW=U:6)E`_=0>4NZ1NPQC]:R=::2;X67%S+IL&G//%YGV>
M$8`!88)]R*J#7+%).UUN*2=W=]#-UK_DB.F_]>\7_H1J7QCJMS'\/O#FDVKE
M&U"&&)B.ZA%X_,BHM:_Y(CIO_7O%_P"A&F^+;&XD\#^'M2MU+/80PS$#^[L7
M)_,"KA;F5_YF3*]G;LCT/0/"=GH6F16MO&JL%'F.!\SMW)-4O%?AN'5=->&1
M`90,PS8^:-QT(/UK8\/>(;#Q'I4-Y9S(Q91YD>?FC;N"*I>,?$-EH6E/)-*K
M7+#;!`IR[N>@`KC7M/:?WC?W>7R//_AYJ;Z+X$\0WG66"5F&>[!/\:K>!-2\
M+6%M)J6MZI%_;%Q(S.TJEF09[''4]:?X#L7U3P-KUH>'GF*_1BO^-7OAT=(O
M-/;1M1M[2/5;21D9)XUW2#/;/4CI7;4M^\]5>W8YX7]TW+SQGX-G@:-M8MY4
M889'1B#^!%<SX%U"RL_B!=Z7I-T)=)OXBZ*,X1P,]_3D?3%>AS^'=(MX6EGM
M+".-1DL\2`#\<5@>#M3L]6\37RZ9H]HNG6?RKJ"H`SMZ+Q]?PK"#CR2Y4[6[
MFDD^979<US2ITN%OK0E+R([@P_BQ_6N?\1ZKKWB^*RT338O(BGXO90?NX['N
M%[^_2K'CSQ1/?:@OA;P^/-OYCMGE0_ZH=QGU]3VI\>B7WAZVM;FWN'FN[9`)
M6;_EH._X=JQY71M5[]/U,JBM)N&W4[/PWH%IX<TB*QM$PJ\LQZNW=C[UL5G:
M-J\&LV*SQ'#CB2//*&M&LW+FU.J+3BG'8Y'QA9-/:EE!+(=PK@*]BOK47,)&
M.:\^U+P^\-\K1IF)I!O3T&><5C5@WJCCQ=!R?/$BL;S[+H$@SC>\G_H-9W@R
M\_XHZ.US_P`L9>/Q-4-3UF,K):0PI#%$[XVL3N[<Y^E97AO5OL&GP_(L@"LI
M1B0"#]*]6GAY+#\CW_X<(KE2CY&R.E=MX"L&!N+]Q@,/+3W]36/IVA-K$MO-
M#&(;22)78@YY[@9KT>RM8[*U2")0J(,`"O*A3<9:]",-AY*?-+H%S:K.OOV-
M</K/PXTG4[@W#6[P3DY,MLVPD^N.E>@45T1G*#O%V/0E%2T9Y9'\*+.1\7&H
M:C+'G[C2\?C7<Z!X:T[P_;>38VR1`_>(Y9OJ>IK:Q153JSFK29,81CLBA?Z>
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M=YCC,BI'L&%P>I[FH='UB\?4HHI[B26*6`R8D51S_L@=!]:MXF;5FV2G3NGR
M[E[0/"MCX?L;BVLUD"SR>8^]MWS5CZ]X!TW6KCSYX7CN1TG@;8_X^M.36[];
M9KXWX9DN?*^S;!AEW8QZYJ?4M:OCJ-XEO,8DM@NQ0$VL2,DON.<?2I5>2?-?
M4'4ARVL8,7PKLI'`NK_4[B(?\LY)_E-=K;Z-;Z9HYT_3T%K'M*KY7!4GN#Z^
M]5FUF4:@R/(D<9L?.VDCA_K67=W=S>VNAS27#(S2H68`=3WISKSEN[AS0C?E
M1:\,>#]*\/7-P]N6DNY?FD>9]TF/\":Z&[M%G3@?-6#+J<EMJ^HNJJYCLPZ_
M*,D^Y]*?IM_<J\#S:FEQY\'F-"5`*GU7';ZU,JCD[LN,TGRI%C2]!AL-0>[B
M,D;MG<BM\C?A6[7(Z-K%[+JD"75TS+.7"@*K1MCD;2.1P.]==2BU;0=)Q:]U
M6"JMU91W"X(YJU15&ARS>"M,9B38VY)Z_NQS21>"-(CP!I]J%'81"NJHJN>7
M<5D5K.R@L;=(8(ECC0855&`*LT45(PHHHH`****`"BBB@!DJ>8A%41I-L!*/
M(C_>_P"L^7[_`-?6M&B@3290.F1;@XC4.%V!L<A?3Z5%;Z+:V\C2QP1I(W5E
M7!K4HHL%D4?[.A2V,,<:(C$DJ!P2>M4HM!M;8B2*VC61<[6"\BMNBE9!RKL8
M-AX<MK<[WC224.7$C*,C)JQ)HEK/<"6:".1EZ%ES6M119"4(I6L95QHUO=2H
MTT,<FW[NY<XJ1])MI(DA:"-HDQM0KP,>E:-%%D/E78SSIL7F-*(U$C#:6QR1
MZ4RWT>VM=[0V\<;OU*K@FM.BG8+(S++1K6TN3<);QK*<_,%YK3HHH!)+8__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
